Articles related to Clinical Pharmacology

Guideline Central offers a complete summary of the ADA’s latest guideline — Standards of Care for 2023. The update and summary cover topics from delaying the onset of T2DM to supporting positive behaviors, glycemic targets, weigh management, technology, pharmacology, and preventing and managing complications and concomitant diseases.

Clinical trials of abaloparatide, a human parathyroid hormone related peptide analog, showed significantly increased bone mineral density at 12 months in the lumbar spine and femoral neck in men with osteoporosis.

The adenoviral vector–based gene therapy contains the gene for interferon alfa-2b. It is administered by catheter into the bladder once every three months. The virus penetrates the bladder endothelial cells and releases the gene, which is incorporated by the cells. As a result, the cells begin secreting high levels of the cancer-fighting interferon.

According to the findings of the study, gabapentin should not be used on a regular basis. Individualization is required, based on the type of pain and the risk of delirium. If gabapentin is used to control postoperative pain, it must be closely monitored for the development of delirium. Low-dose opioids, along with nonpharmacologic pain management strategies such as postoperative physical therapy and mobilization, can still be used safely in the study population. Rather than relying on a single medication, a more holistic approach to postoperative pain control in the hospital setting is required.

The only effective ways to treat TEC are to stop, delay, or modify your patients’ chemotherapy dose. Supportive medications, such as topical keratolytics, wound care, and high-potency topical corticosteroids, respond differently. These medications cause a 2- to 4-week recovery period following the interruption of chemotherapy, which is a somewhat gradual improvement.

In comparison to 72% of patients who received placebo, 45% of those who received teplizumab-mzwv (Tzield, Provention Bio) over the course of a median follow-up of 51 months were found to have stage 3 type 1 diabetes. Teplizumab-mzwv appeared to delay the onset of type 1 diabetes by about two years, as the median time from randomization to diagnosis of stage 3 diabetes was 50 months in the teplizumab-mzwv group and 25 months in the placebo group.